Tonix Pharmaceuticals (TNXP) Competitors $29.77 -0.74 (-2.43%) Closing price 04:00 PM EasternExtended Trading$29.43 -0.34 (-1.14%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. RENB, ADAP, VIRI, SLN, COYA, SGMT, NKTX, EDIT, KYTX, and DERMShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Renovaro (RENB), Adaptimmune Therapeutics (ADAP), Virios Therapeutics (VIRI), Silence Therapeutics (SLN), Coya Therapeutics (COYA), Sagimet Biosciences (SGMT), Nkarta (NKTX), Editas Medicine (EDIT), Kyverna Therapeutics (KYTX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Renovaro Adaptimmune Therapeutics Virios Therapeutics Silence Therapeutics Coya Therapeutics Sagimet Biosciences Nkarta Editas Medicine Kyverna Therapeutics Journey Medical Tonix Pharmaceuticals (NASDAQ:TNXP) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Does the media refer more to TNXP or RENB? In the previous week, Tonix Pharmaceuticals had 20 more articles in the media than Renovaro. MarketBeat recorded 21 mentions for Tonix Pharmaceuticals and 1 mentions for Renovaro. Renovaro's average media sentiment score of 1.87 beat Tonix Pharmaceuticals' score of -0.11 indicating that Renovaro is being referred to more favorably in the news media. Company Overall Sentiment Tonix Pharmaceuticals Neutral Renovaro Very Positive Does the MarketBeat Community believe in TNXP or RENB? Tonix Pharmaceuticals received 341 more outperform votes than Renovaro when rated by MarketBeat users. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34160.78% Underperform Votes22039.22% RenovaroN/AN/A Which has more risk and volatility, TNXP or RENB? Tonix Pharmaceuticals has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Which has preferable valuation and earnings, TNXP or RENB? Renovaro has lower revenue, but higher earnings than Tonix Pharmaceuticals. Renovaro is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.09M5.51-$116.66M-$2.54 thousand-0.01RenovaroN/AN/A-$80.65M-$0.93-0.72 Do analysts prefer TNXP or RENB? Tonix Pharmaceuticals presently has a consensus price target of $585.00, indicating a potential upside of 1,865.07%. Given Tonix Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Tonix Pharmaceuticals is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TNXP or RENB more profitable? Renovaro has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Renovaro's return on equity of -61.84% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,197.86% -163.95% -118.88% Renovaro N/A -61.84%-48.07% Do institutionals & insiders have more ownership in TNXP or RENB? 82.3% of Tonix Pharmaceuticals shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 0.0% of Tonix Pharmaceuticals shares are held by insiders. Comparatively, 21.7% of Renovaro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryTonix Pharmaceuticals beats Renovaro on 9 of the 16 factors compared between the two stocks. Remove Ads Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.64M$6.99B$5.68B$8.31BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-0.017.2324.5519.25Price / Sales5.51230.77395.7294.09Price / CashN/A65.6738.1634.64Price / Book0.016.617.064.46Net Income-$116.66M$142.13M$3.19B$247.07M7 Day Performance45.01%2.79%1.49%3.05%1 Month Performance269.81%2.70%5.87%-2.85%1 Year Performance-97.16%-4.42%14.94%4.63% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals2.2863 of 5 stars$29.77-2.4%$585.00+1,865.1%-97.2%$55.64M$10.09M-0.0150Earnings ReportNews CoverageGap UpHigh Trading VolumeRENBRenovaro0.9429 of 5 stars$0.75-6.5%N/A-77.8%$120.15MN/A-0.8120Positive NewsGap UpADAPAdaptimmune Therapeutics2.1859 of 5 stars$0.47+3.5%$2.79+498.2%-80.8%$119.50M$175.04M-2.12490Earnings ReportNews CoverageVIRIVirios Therapeutics0.2495 of 5 stars$6.12-20.8%$3.00-51.0%+1,283.9%$117.86MN/A-22.675Gap UpSLNSilence Therapeutics2.7723 of 5 stars$3.93+0.5%$40.67+934.8%-84.1%$117.63M$43.26M-2.50100Positive NewsGap DownCOYACoya Therapeutics2.1971 of 5 stars$7.01+8.0%$16.25+131.8%-31.6%$117.12M$9.55M-10.786Earnings ReportSGMTSagimet Biosciences2.4786 of 5 stars$3.78+0.9%$23.00+509.3%-8.4%$115.80M$2M-2.648NKTXNkarta2.0761 of 5 stars$1.63-2.1%$15.00+823.1%-82.6%$114.68MN/A-0.86140EDITEditas Medicine4.2683 of 5 stars$1.37-6.5%$6.83+400.6%-81.4%$113.26M$32.31M-0.53230Positive NewsGap DownKYTXKyverna Therapeutics1.1295 of 5 stars$2.61+4.2%$18.40+606.3%-90.9%$112.46M$7.03M0.0096DERMJourney Medical2.6014 of 5 stars$5.33+1.4%$9.67+81.5%+98.2%$111.24M$57.77M-5.6690 Remove Ads Related Companies and Tools Related Companies Renovaro Alternatives Adaptimmune Therapeutics Alternatives Virios Therapeutics Alternatives Silence Therapeutics Alternatives Coya Therapeutics Alternatives Sagimet Biosciences Alternatives Nkarta Alternatives Editas Medicine Alternatives Kyverna Therapeutics Alternatives Journey Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TNXP Stock Free TNXP Stock Alerts